Hallmarks in colorectal cancer: Angiogenesis and cancer stem-like cells

World Journal of Gastroenterology

Volumn 20, Issue 15, 2014, Pages 4189-4196

  Mathonnet, Muriel ^a,b   Perraud, Aurelie ^a,b   Christou, Niki ^a   Akil, Hussein ^b   Melin, Carole ^a,b   Battu, Serge ^b   Jauberteau, Marie Odile ^b   Denizot, Yves ^c  

^a LIMOGES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF LIMOGES   (France)

^c UNIVERSITÉ DE LIMOGES   (France)

Author keywords

Cancer stem like cell; Colon cancer; Microenvironment; Stem cell; Tumor initiating cell

Indexed keywords

ABC TRANSPORTER; APC PROTEIN; B RAF KINASE; BETA CATENIN; BEVACIZUMAB; BMI1 PROTEIN; BONE MORPHOGENETIC PROTEIN; CD133 ANTIGEN; CELL SURFACE PROTEIN; ENDOTHELIN 1; FLUOROURACIL; FOLINIC ACID; HERMES ANTIGEN; INTERLEUKIN 6; IRINOTECAN; K RAS PROTEIN; NOTCH RECEPTOR; OCTAMER TRANSCRIPTION FACTOR 4; OXALIPLATIN; SCATTER FACTOR; SONIC HEDGEHOG PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR SOX2; TRANSFORMING GROWTH FACTOR BETA; TROPOMYOSIN; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; VASCULOTROPIN; MONOCLONAL ANTIBODY; TUMOR MARKER; VASCULOTROPIN A;

ANGIOGENESIS; ARTICLE; CANCER STEM CELL; CARCINOMA; ENDOTHELIAL PROGENITOR CELL; EPITHELIAL MESENCHYMAL TRANSITION; FLUORESCENCE ACTIVATED CELL SORTING; HOMEOSTASIS; HUMAN; HYPOXIA; INTESTINE CRYPT; INTESTINE EPITHELIUM CELL; MESENCHYMAL STEM CELL; META ANALYSIS (TOPIC); METASTATIC COLORECTAL CANCER; MYOFIBROBLAST; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL; TISSUE REPAIR; TUMOR GROWTH; TUMOR MICROENVIRONMENT; WNT SIGNALING PATHWAY; ANIMAL; ANOXIA; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL TUMOR; CYTOLOGY; DRUG RESISTANCE; INTESTINE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TREATMENT OUTCOME; TUMOR RECURRENCE; VASCULARIZATION;

ANIMALS; ANOXIA; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; INTESTINES; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84898876965     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i15.4189     Document Type: Article

References (67)

1. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 1989; 8: 98-101 [PMID: 2673568]
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70 [PMID: 10647931 DOI: 10.1016/S0092-8674(00)81683-9]
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674 [PMID: 21376230 DOI: 10.1016/j.cell.2011.02.013]
4. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438: 932-936 [PMID: 16355210 DOI: 10.1038/nature04478]
5. Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B, Andreeff M, Marini F. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 2009; 4: e4992 [PMID: 19352430 DOI: 10.1371/journal. pone.0004992]
6. Quante M, Tu SP, Tomita H, Gonda T, Wang SS, Takashi S, Baik GH, Shibata W, Diprete B, Betz KS, Friedman R, Varro A, Tycko B, Wang TC. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 2011; 19: 257-272 [PMID: 21316604 DOI: 10.1016/j.ccr.2011.01.020]
7. Sun Y, Nelson PS. Molecular pathways: involving microenvironment damage responses in cancer therapy resistance. Clin Cancer Res 2012; 18: 4019-4025 [PMID: 22619305 DOI: 10.1158/1078-0432.CCR-11-0768]
8. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-760 [PMID: 17051156 DOI: 10.1038/nature05236]
9. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F, Tripodo C, Russo A, Gulotta G, Medema JP, Stassi G. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007; 1: 389-402 [PMID: 18371377 DOI: 10.1016/ j.stem.2007.08.001]
10. Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, van Buren G, Samuel S, Kim MP, Lim SJ, Ellis LM. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 2009; 69: 1951-1957 [PMID: 19244128 DOI: 10.1158/0008-5472.CAN-08-2023]
11. Dieter SM, Ball CR, Hoffmann CM, Nowrouzi A, Herbst F, Zavidij O, Abel U, Arens A, Weichert W, Brand K, Koch M, Weitz J, Schmidt M, von Kalle C, Glimm H. Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell 2011; 9: 357-365 [PMID: 21982235 DOI: 10.1016/j.stem.2011.08.010]
12. Maugeri-Saccà M, Vigneri P, De Maria R. Cancer stem cells and chemosensitivity. Clin Cancer Res 2011; 17: 4942-4947 [PMID: 21622723 DOI: 10.1158/1078-0432.CCR-10-2538]
13. Catalano V, Turdo A, Di Franco S, Dieli F, Todaro M, Stassi G. Tumor and its microenvironment: a synergistic interplay. Semin Cancer Biol 2013; 23: 522-532 [PMID: 24012661 DOI: 10.1016/j.semcancer.2013.08.007]
14. Ricci-Vitiani L, Fabrizi E, Palio E, De Maria R. Colon cancer stem cells. J Mol Med (Berl) 2009; 87: 1097-1104 [PMID: 19727638 DOI: 10.1007/s00109-009-0518-4]
15. Tian H, Biehs B, Warming S, Leong KG, Rangell L, Klein OD, de Sauvage FJ. A reserve stem cell population in small intestine renders Lgr5-positive cells dispensable. Nature 2011; 478: 255-259 [PMID: 21927002 DOI: 10.1038/nature10408]
16. Vaiopoulos AG, Kostakis ID, Koutsilieris M, Papavassiliou AG. Colorectal cancer stem cells. Stem Cells 2012; 30: 363-371 [PMID: 22232074 DOI: 10.1002/stem.1031]
17. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-648 [PMID: 7509044 DOI: 10.1038/367645a0]
18. Fábián A, Barok M, Vereb G, Szöllosi J. Die hard: are cancer stem cells the Bruce Willises of tumor biology? Cytometry A 2009; 75: 67-74 [PMID: 19051297 DOI: 10.1002/cyto.a.20690]
19. Shaker A, Rubin DC. Intestinal stem cells and epithelialmesenchymal interactions in the crypt and stem cell niche. Transl Res 2010; 156: 180-187 [PMID: 20801415 DOI: 10.1016/ j.trsl.2010.06.003]
20. Roy S, Majumdar AP. Cancer Stem Cells in Colorectal Cancer: Genetic and Epigenetic Changes. J Stem Cell Res Ther 2012; (6): pii: 10342 [PMID: 23565347 DOI: 10.4172/2157-7633. S7-006]
21. Chowdhury S, Howell GM, Rajput A, Teggart CA, Brattain LE, Weber HR, Chowdhury A, Brattain MG. Identification of a novel TGFβ/PKA signaling transduceome in mediating control of cell survival and metastasis in colon cancer. PLoS One 2011; 6: e19335 [PMID: 21559296 DOI: 10.1371/journal. pone.0019335]
22. Sikandar SS, Pate KT, Anderson S, Dizon D, Edwards RA, Waterman ML, Lipkin SM. NOTCH signaling is required for formation and self-renewal of tumor-initiating cells and for repression of secretory cell differentiation in colon cancer. Cancer Res 2010; 70: 1469-1478 [PMID: 20145124 DOI: 10.1158/0008-5472.CAN-09-2557]
23. Humphries A, Wright NA. Colonic crypt organization and tumorigenesis. Nat Rev Cancer 2008; 8: 415-424 [PMID: 18480839 DOI: 10.1038/nrc2392]
24. Akil H, Perraud A, Mélin C, Jauberteau MO, Mathonnet M. Fine-tuning roles of endogenous brain-derived neurotrophic factor, TrkB and sortilin in colorectal cancer cell survival. PLoS One 2011; 6: e25097 [PMID: 21966426 DOI: 10.1371/ journal.pone.0025097]
25. Smit MA, Geiger TR, Song JY, Gitelman I, Peeper DS. A Twist-Snail axis critical for TrkB-induced epithelial-mesenchymal transition-like transformation, anoikis resistance, and metastasis. Mol Cell Biol 2009; 29: 3722-3737 [PMID: 19414595 DOI: 10.1128/MCB.01164-08]
26. Fujikawa H, Tanaka K, Toiyama Y, Saigusa S, Inoue Y, Uchida K, Kusunoki M. High TrkB expression levels are associated with poor prognosis and EMT induction in colorectal cancer cells. J Gastroenterol 2012; 47: 775-784 [PMID: 22361863 DOI: 10.1007/s00535-012-0532-0]
27. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, Haegebarth A, Korving J, Begthel H, Peters PJ, Clevers H. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007; 449: 1003-1007 [PMID: 17934449 DOI: 10.1038/nature06196]
28. Sangiorgi E, Capecchi MR. Bmi1 is expressed in vivo in intestinal stem cells. Nat Genet 2008; 40: 915-920 [PMID: 18536716 DOI: 10.1038/ng.165]
29. Liu K, Lin B, Zhao M, Yang X, Chen M, Gao A, Liu F, Que J, Lan X. The multiple roles for Sox2 in stem cell maintenance and tumorigenesis. Cell Signal 2013; 25: 1264-1271 [PMID: 23416461 DOI: 10.1016/j.cellsig.2013.02.013]
30. Chang CJ, Chien Y, Lu KH, Chang SC, Chou YC, Huang CS, Chang CH, Chen KH, Chang YL, Tseng LM, Song WS, Wang JJ, Lin JK, Huang PI, Lan YT. Oct4-related cytokine effects regulate tumorigenic properties of colorectal cancer cells. Biochem Biophys Res Commun 2011; 415: 245-251 [PMID: 22037460 DOI: 10.1016/j.bbrc.2011.10.024]
31. Tomlinson MJ, Tomlinson S, Yang XB, Kirkham J. Cell separation: Terminology and practical considerations. J Tissue Eng 2013; 4: 2041731412472690 [PMID: 23440031 DOI: 10.1177/2041731412472690]
32. Cammareri P, Lombardo Y, Francipane MG, Bonventre S, Todaro M, Stassi G. Isolation and culture of colon cancer stem cells. Methods Cell Biol 2008; 86: 311-324 [PMID: 18442654 DOI: 10.1016/S0091-679X(08)00014-9]
33. Bauer J. Advances in cell separation: recent developments in counterflow centrifugal elutriation and continuous flow cell separation. J Chromatogr B Biomed Sci Appl 1999; 722: 55-69 [PMID: 10068133 DOI: 10.1016/SO378-4347(98)00308-9]
34. Mélin C, Perraud A, Akil H, Jauberteau MO, Cardot P, Mathonnet M, Battu S. Cancer stem cell sorting from colorectal cancer cell lines by sedimentation field flow fractionation. Anal Chem 2012; 84: 1549-1556 [PMID: 22236375 DOI: 10.1021/ac202797z]
35. Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, Maira G, Parati EA, Stassi G, Larocca LM, De Maria R. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010; 468: 824-828 [PMID: 21102434 DOI: 10.1038/nature09557]
36. Vermeulen L, De Sousa E Melo F, van der Heijden M, Cameron K, de Jong JH, Borovski T, Tuynman JB, Todaro M, Merz C, Rodermond H, Sprick MR, Kemper K, Richel DJ, Stassi G, Medema JP. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 2010; 12: 468-476 [PMID: 20418870 DOI: 10.1038/ncb2048]
37. Medema JP, Vermeulen L. Microenvironmental regulation of stem cells in intestinal homeostasis and cancer. Nature 2011; 474: 318-326 [PMID: 21677748 DOI: 10.1038/nature10212]
38. Erez N, Truitt M, Olson P, Arron ST, Hanahan D. Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NFkappaB-Dependent Manner. Cancer Cell 2010; 17: 135-147 [PMID: 20138012 DOI: 10.1016/j.ccr.2009.12.041]
39. Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Cell 2005; 7: 513-520 [PMID: 15950901 DOI: 10.1016/j.ccr.2005.05.024]
40. Togo S, Polanska UM, Horimoto Y, Orimo A. Carcinomaassociated fibroblasts are a promising therapeutic target. Cancers (Basel) 2013; 5: 149-169 [PMID: 24216702 DOI: 10.3390/cancers5010149]
41. Stagg J. Mesenchymal stem cells in cancer. Stem Cell Rev 2008; 4: 119-124 [PMID: 18493880 DOI: 10.1007/s12015-008-9030-4]
42. Liu Y, Han ZP, Zhang SS, Jing YY, Bu XX, Wang CY, Sun K, Jiang GC, Zhao X, Li R, Gao L, Zhao QD, Wu MC, Wei LX. Effects of inflammatory factors on mesenchymal stem cells and their role in the promotion of tumor angiogenesis in colon cancer. J Biol Chem 2011; 286: 25007-25015 [PMID: 21592963 DOI: 10.1074/jbc.M110.213108]
43. Mishra PJ, Mishra PJ, Humeniuk R, Medina DJ, Alexe G, Mesirov JP, Ganesan S, Glod JW, Banerjee D. Carcinomaassociated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res 2008; 68: 4331-4339 [PMID: 18519693 DOI: 10.1158/0008-5472.CAN-08-0943]
44. Tsai KS, Yang SH, Lei YP, Tsai CC, Chen HW, Hsu CY, Chen LL, Wang HW, Miller SA, Chiou SH, Hung MC, Hung SC. Mesenchymal stem cells promote formation of colorectal tumors in mice. Gastroenterology 2011; 141: 1046-1056 [PMID: 21699785 DOI: 10.1053/j.gastro.2011.05.045]
45. Huang WH, Chang MC, Tsai KS, Hung MC, Chen HL, Hung SC. Mesenchymal stem cells promote growth and angiogenesis of tumors in mice. Oncogene 2013; 32: 4343-4354 [PMID: 23085755 DOI: 10.1038/onc.2012.458]
46. Eldesoky A, Shouma A, Mosaad Y, Elhawary A. Clinical relevance of serum vascular endothelial growth factor and interleukin-6 in patients with colorectal cancer. Saudi J Gastroenterol 2011; 17: 170-173 [PMID: 21546718 DOI: 10.4103/1319-3767.80378]
47. Chung YC, Chang YF. Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol 2003; 83: 222-226 [PMID: 12884234 DOI: 10.1002/jso.10269]
48. Knüpfer H, Preiss R. Serum interleukin-6 levels in colorectal cancer patients--a summary of published results. Int J Colorectal Dis 2010; 25: 135-140 [PMID: 19898853 DOI: 10.1007/s00384-009-0818-8]
49. Komoda H, Tanaka Y, Honda M, Matsuo Y, Hazama K, Takao T. Interleukin-6 levels in colorectal cancer tissues. World J Surg 1998; 22: 895-898 [PMID: 9673566 DOI: 10.1007/ s002689900489]
50. Middleton K, Jones J, Lwin Z, Coward JI. Interleukin-6: an angiogenic target in solid tumours. Crit Rev Oncol Hematol 2014; 89: 129-139 [PMID: 24029605 DOI: 10.1016/j.critrevonc.2013.08.004]
51. Huang H, Bhat A, Woodnutt G, Lappe R. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 2010; 10: 575-585 [PMID: 20651738 DOI: 10.1038/nrc2894]
52. Cao Y. Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci Signal 2009; 2: re1 [PMID: 19244214 DOI: 10.1126/scisignal.259re1]
53. Brahimi-Horn MC, Bellot G, Pouysségur J. Hypoxia and energetic tumour metabolism. Curr Opin Genet Dev 2011; 21: 67-72 [PMID: 21074987 DOI: 10.1016/j.gde.2010.10.006]
54. Nagy JA, Chang SH, Shih SC, Dvorak AM, Dvorak HF. Heterogeneity of the tumor vasculature. Semin Thromb Hemost 2010; 36: 321-331 [PMID: 20490982 DOI: 10.1055/ s-0030-1253454]
55. Patenaude A, Parker J, Karsan A. Involvement of endothelial progenitor cells in tumor vascularization. Microvasc Res 2010; 79: 217-223 [PMID: 20085777 DOI: 10.1016/j.mvr.2010.01.007]
56. Wagner AD, Arnold D, Grothey AA, Haerting J, Unverzagt S. Anti-angiogenic therapies for metastatic colorectal cancer. Cochrane Database Syst Rev 2009; (3): CD005392 [PMID: 19588372 DOI: 10.1002/14651858.CD005392.pub3]
57. de Gramont A, Van Cutsem E, Schmoll HJ, Tabernero J, Clarke S, Moore MJ, Cunningham D, Cartwright TH, Hecht JR, Rivera F, Im SA, Bodoky G, Salazar R, Maindrault-Goebel F, Shacham-Shmueli E, Bajetta E, Makrutzki M, Shang A, André T, Hoff PM. Bevacizumab plus oxaliplatinbased chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 2012; 13: 1225-1233 [PMID: 23168362 DOI: 10.1016/ S1470-2045(12)70509-0]
58. Eveno C, Pocard M. VEGF levels and the angiogenic potential of the microenvironment can affect surgical strategy for colorectal liver metastasis. Cell Adh Migr 2012; 6: 569-573 [PMID: 23257830 DOI: 10.4161/cam.23247]
59. Yu ZQ, Zhang C, Wang H, Lao XY, Chai R, Gao XH, Cao GW, Fu CG. Downregulation of ATP-binding cassette subfamily C member 4 increases sensitivity to neoadjuvant radiotherapy for locally advanced rectal carcinoma. Dis Colon Rectum 2013; 56: 600-608 [PMID: 23575399 DOI: 10.1097/ DCR.0b013e31827c2b80]
60. Zhang Z, Huang J. Intestinal stem cells-types and markers. Cell Biol Int 2013; 37: 406-414 [PMID: 23471862 DOI: 10.1002/cbin.10049]
61. Lin SP, Lee YT, Yang SH, Miller SA, Chiou SH, Hung MC, Hung SC. Colon cancer stem cells resist antiangiogenesis therapy-induced apoptosis. Cancer Lett 2013; 328: 226-234 [PMID: 23017941 DOI: 10.1016/j.canlet.2012.08.036]
62. Francipane MG, Alea MP, Lombardo Y, Todaro M, Medema JP, Stassi G. Crucial role of interleukin-4 in the survival of colon cancer stem cells. Cancer Res 2008; 68: 4022-4025 [PMID: 18519657 DOI: 10.1158/0008-5472.CAN-07-6874]
63. AJCC Cancer Staging Manual. 7th ed. New York: Springer, 2010: 143-164
64. Zhou SW, Huang YY, Wei Y, Jiang ZM, Zhang YD, Yang Q, Xie DR. No survival benefit from adding cetuximab or panitumumab to oxaliplatin-based chemotherapy in the first-line treatment of metastatic colorectal cancer in KRAS wild type patients: a meta-analysis. PLoS One 2012; 7: e50925 [PMID: 23226426 DOI: 10.1371/journal.pone.0050925]
65. Perez-Villamil B, Romera-Lopez A, Hernandez-Prieto S, Lopez-Campos G, Calles A, Lopez-Asenjo JA, Sanz-Ortega J, Fernandez-Perez C, Sastre J, Alfonso R, Caldes T, Martin-Sanchez F, Diaz-Rubio E. Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior. BMC Cancer 2012; 12: 260 [PMID: 22712570 DOI: 10.1186/1471-2407-12-2 60]
66. Schlicker A, Beran G, Chresta CM, McWalter G, Pritchard A, Weston S, Runswick S, Davenport S, Heathcote K, Castro DA, Orphanides G, French T, Wessels LF. Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines. BMC Med Genomics 2012; 5: 66 [PMID: 23272949 DOI: 10.1186/1755-8794-5-66]
67. Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, Ostos LC, Lannon WA, Grotzinger C, Del Rio M, Lhermitte B, Olshen AB, Wiedenmann B, Cantley LC, Gray JW, Hanahan D. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 2013; 19: 619-625 [PMID: 23584089 DOI: 10.1038/nm.3175]